What do systematic reviews say?

Adaptive servo ventilation (ASV) vs bilevel ventilation

The review found no eligible studies for this question.

• Non‐invasive positive pressure ventilation for central sleep apnoea in adults 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
• Non‐invasive positive pressure ventilation for central sleep apnoea in adults 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Adaptive servo ventilation (ASV) plus best supportive care vs best supportive care alone or inactive control

The review found no eligible studies for this question.

• Non‐invasive positive pressure ventilation for central sleep apnoea in adults 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Continuous positive airway pressure (CPAP) plus best supportive care vs best supportive care

Continuous positive airway pressure (CPAP) plus best supportive care may leads to lower time to life‐saving cardiovascular intervention ( compared with best supportive care (low certainty).

• Non‐invasive positive pressure ventilation for central sleep apnoea in adults 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 56 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 183 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

Summary of findings table ‐ Systemic therapy showed no clear difference in change in grip strength from baseline to end of intervention compared with control (low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 1.08 [0.37, 3.17]
  1 study · 137 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1099 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 295 participants
  Very low

Duct‐to‐mucosa pancreaticojejunostomy using the modified Blumgart technique vs duct‐to‐mucosa pancreaticojejunostomy using the traditional interrupted technique

It is very uncertain whether duct‐to‐mucosa pancreaticojejunostomy using the modified Blumgart… changes rate of surgical reintervention compared with duct‐to‐mucosa pancreaticojejunostomy using the traditional… (very low certainty).

• Duct‐to‐mucosa versus other types of pancreaticojejunostomy for the prevention of postoperative pancreatic fistula… 2022 · Cochrane Headline outcomes only
  RR 1.93 [0.18, 20.91]
  1 study · 210 participants
  Very low

Duct‐to‐mucosa vs invagination pancreaticojejunostomy

It is very uncertain whether duct‐to‐mucosa changes rate of surgical reintervention compared with invagination pancreaticojejunostomy (very low certainty).

• Duct‐to‐mucosa versus other types of pancreaticojejunostomy for the prevention of postoperative pancreatic fistula… 2022 · Cochrane Headline outcomes only
  RR 1.12 [0.65, 1.95]
  10 studies · 1472 participants
  Very low

Cuffed vs uncuffed endotracheal tubes

• Cuffed versus uncuffed endotracheal tubes for neonates 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 69 participants
  Very low

Prophylactic dopamine antagonist antiemetic medications vs placebo

• Prophylactic antiemetics for adults receiving intravenous opioids in the acute care setting 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 191 participants
  Low

Cervical pessary vs vaginal progesterone

• Cervical pessary for preventing preterm birth in singleton pregnancies 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 11 participants
  Low

Cervical pessary vs cervical cerclage

• Cervical pessary for preventing preterm birth in singleton pregnancies 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 13 participants
  Low

Cervical pessary vs no treatment

The review found no eligible studies for this question.

• Cervical pessary for preventing preterm birth in singleton pregnancies 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Continuous vs intermittent bolus (nasogastric and orogastric tube) milk feeding ‐ all preterm infants less than 1500 grams

• Continuous nasogastric milk feeding versus intermittent bolus milk feeding for preterm infants less than 1500 grams 2021 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 433 participants
  Very low

Continuous vs intermittent bolus (nasogastric and orogastric tube) milk feeding ‐ all preterm infants less than 1500 grams

• Continuous nasogastric milk feeding versus intermittent bolus milk feeding for preterm infants less than 1500 grams 2021 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 433 participants
  Low

Continuous vs intermittent bolus (nasogastric and orogastric tube) milk feeding ‐ all preterm infants less than 1500 grams

• Continuous nasogastric milk feeding versus intermittent bolus milk feeding for preterm infants less than 1500 grams 2021 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 433 participants
  Low

Dipyridamole vs placebo

The review found no eligible studies for this question.

• Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dipyridamole plus aspirin vs placebo

The review found no eligible studies for this question.

• Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found